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Results: Results: in the 4 groups the results in terms of D90 
are respectively 123±32Gy, 146±28Gy, 153±23Gy, 166±17Gy, 
as shown in Figure 1. The dose fall-off in terms of D90 is 
respectively 58Gy, 43Gy, 37Gy, 21Gy (as shown in Figure 2) 
and in terms of V100 17%, 10%, 8%, 4%. In the last group the 
mean theoretical D90 and V100 are 187Gy and 99%, against a 
real implant evaluation of 186Gy and 99%and the maximum 
urethra dose is 210Gy in the planning and 219Gy at the end of 
the implant. In the 30% of the patients of the “real-time” 
group we changed the number of seeds or needles 
composition during the implant, to reach the desired 
constraints and PTV coverage. 
 
 
Conclusion: Conclusion: our work shows the impact of the 
“image-guided” technology evolution on the dose fall-off 
both in terms of D90 and V100. Moreover, we show how the 
“real-time” method allows to change the “theoretical” plan 
during the implant, to reach the recommended constraints 
and PTV coverage [1]. 
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Purpose or Objective: We initially reported biochemical 
control rate of 97% at 4 years of followup (Brachytherapy, 
2009), which highlighted our methodology of limiting needle 
trauma, relying on Intra-operative, Real-Time computer 
assisted IO (Inverse Optimization) to reduce the number of 
sources and total activity without compromising dosimetric 
quality. This update was performed to confirm our earlier 
favorable BFFS outcomes. 
 
Material and Methods: Between 2001 and 2013, 491 patients 
underwent real-time IO-PSI. Only patients with a minimum of 
2 years of follow-up treated without supplemental IMRT were 
the subject of this analysis (N=315). Our dose objectives and 
constraints for real-time IO-PSI have previously been 
published and remain unchanged. The main dose objective 
intra-operatively was to achieve a V100 > 95% (Volume 
receiving > 95% of the prescribed dose). Patients were 
implanted with either 125I (PD=145 Gy) or 103Pd (PD =120 Gy). 
Toxicity was prospectively scored using the Radiation 
Oncology Group Toxicity scale and the International Prostate 
Symptom Score questionnaire. Biochemical control was 
determined using the nadir+2 ng/ml definition.  
 
Results: The mean and median followup was 58 and 54 
months respectively (range: 24-110 months). The NCCN risk 
classification for FR and IR patients were used. 125I sources 
were used for 93% of the implants, and 103Pd for 7%. 89% of 
patients presented with FR disease while 10% presented with 
IR, and in 2 cases HR. (1%). The median number of sources 
and total activity implanted were 65 and 999MBq, 
respectively. The median prostate volume implanted was 36 
cc. The median V100 was 95%. Absolute BNED was 97%. The 
10 year actuarial probability of biochemical control rate for 
all patients was 95%, with no difference observed between FR 
or IR patients (97% and 95% respectively) Late Gu and GI 
Grade 2 and higher toxicity was very low. With a minimum 
follow-up for 2 years, the late Grade 2 and Grade 3 GU 
toxicity was 19% and 1% respectively. The late Grade 2 and 3 
rectal bleeding rate was 1% and 0% respectively, with no 
Grade 4 toxicity observed.  
 
Conclusion: With extended follow-up of 10 years, real-time 
IO-PSI demonstrated excellent biochemical control rates with 
low incidence of toxicity confirming the validity of our 
original hypothesis and methodology of Inverse planning in 
real time for PSI, and comparing favorably to other 
alternatives at lower cost in the USA. 
 
 
 
 
Poster: Radiobiology track: Molecular targeted agents and 
radiotherapy  
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Purpose or Objective: Despite aggressive treatment with 
radiation therapy plus temozolomide (TMZ), the prognosis for 
glioblastoma remains poor. We investigated the potential of 
targeting signal transducer and activator of transcription-3 
(STAT3) to improve the therapeutic outcome of glioblastoma. 
 
Material and Methods: We evaluated the preclinical 
potential of a STAT3 inhibitor, Cpd188 combined with 
temozolomide and radiation in vitro assays using two 
established glioblastoma cell lines (U251, U87) and two 
patients-derived glioblastoma cell lines (GBL12, GBL28) and 
in vivo studies using nude mice bearing intracranial U251 
xenografts. 
 
Results: Cpd188 potentiated the radiosensitizing effect of 
TMZ in U251 cell which has high levels of p-STAT3 expression. 
Increased radiosensitizing effects of TMZ were associated 
with impaired DNA damage repair, apoptosis and the 
reversion of epithelial-mesenchymal transition (EMT). Cpd188 
delayed in vivo tumor growth both alone and in combination 
